Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLG | P00747 | 1/20 | 0.43 |
| ▸ | PLAT | P00750 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | MMP12 | P39900 | 4/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | ANPEP | P15144 | 1/20 | 0.36 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.36 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL7418767 | 1.00 | PLG (0.43) | PLGPLATLMNAKMT2ATDP1 | |
| SCHEMBL940065 | 0.91 | PLG (0.52) | PLGPLATLMNAKMT2ATDP1 | |
| SCHEMBL7430073 | 0.91 | PLG (0.52) | PLGPLATLMNAKMT2ATDP1 | |
| SCHEMBL31270861 | 0.80 | — | — | |
| SCHEMBL6294396 | 0.79 | TDP1 (0.39) | KMT2ATDP1MMP12SMN1; SMN2ALDH1A1 | |
| SCHEMBL8596354 | 0.79 | KMT2A (0.46) | PLGPLATLMNAKMT2ATDP1 | |
| SCHEMBL8595703 | 0.79 | KMT2A (0.46) | PLGPLATLMNAKMT2ATDP1 | |
| Trifluoroacetic Acid SCHEMBL1127872 | 0.75 | PLG (0.42) | PLGPLATLMNAKMT2AANPEP | |
| Trifluoroacetic Acid SCHEMBL21813736 | 0.75 | CYP2D6 (0.52) | TDP1ALDH1A1CYP3A4EPHX1EPHX2 | |
| SCHEMBL939950 | 0.74 | TDP1 (0.37) | KMT2ATDP1ALDH1A1CYP3A4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160361295-A1 | FURO[3, 2-B] PYRR0L-3-ONES AS CATHESPIN S INHIBITORS | AMURA THERAPEUTICS LTD (GB) | 2016-12-15 | — | — | US | disclosed |
| CN-101506185-B | Oxolane is [3,2-B] pyrroles-3-ketone intermediate also | 格兰泰有限公司 | 2016-06-29 | — | — | CN | disclosed |
| US-20160015685-A1 | FURO [3, 2-B] PYRR0L-3-0NES AS CATHESPIN S INHIBITORS | AMURA THERAPEUTICS LTD (GB) | 2016-01-21 | — | — | US | disclosed |
| US-20150209349-A1 | Piperazine Compounds | AMURA THERAPEUTICS LTD (GB) | 2015-07-30 | — | — | US | disclosed |
| EP-2240491-B1 | TETRAHYDROFURO(2,3-b)PYRROL-3-ONE DERIVATIVES AS INHIBITORS OF CYSTEINE PROTEINASES | AMURA THERAPEUTICS LTD (GB) | 2015-07-15 | — | — | EP | disclosed |
| US-20150164912-A1 | FURO[3, 2-B] PYRR0L-3-ONES AS CATHESPIN S INHIBITORS | AMURA THERAPEUTICS LTD (GB) | 2015-06-18 | — | — | US | disclosed |
| US-9045492-B2 | Piperazine compounds | AMURA THERAPEUTICS LIMITED (GB) | 2015-06-02 | — | — | US | disclosed |
| US-8933109-B2 | Furo[3, 2-B] pyrrol-3-ones as cathespin S inhibitors | AMURA LIMITED (GB) | 2015-01-13 | — | — | US | disclosed |
| US-8877927-B2 | Furo[3,2-B] pyrrol -3-one derivatives and their use as cysteinyl proteinase inhibitors | GRUNENTHAL GMBH (DE) | 2014-11-04 | — | — | US | disclosed |
| EP-2719700-A1 | TETRAHYDROFURO(3,2-B)PYRROL-3-ONE DERIVATIVES AS INHIBITORS OF CYSTEINE PROTEINASES | Amura Therapeutics Limited (GB) | 2014-04-16 | — | — | EP | disclosed |
| US-20030203900-A1 | Cysteine protease inhibitors | MEDIVIR UK LTD (GB) | 2003-10-30 | — | — | US | disclosed |
| US-20030186962-A1 | Cysteine protease inhibitors | MEDIVIR AB (SE) | 2003-10-02 | — | — | US | disclosed |
| EP-1345931-A2 | CYSTEINE PROTEASE INHIBITORS | Medivir UK Ltd (GB) | 2003-09-24 | — | — | EP | disclosed |
| WO-2002057248-A2 | INHIBITORS OF CRUZIPAIN AND OTHER CYSTEINE PROTEASES | AMURA THERAPEUTICS LIMITED (GB) | 2002-07-25 | — | — | WO | disclosed |
| WO-2002057249-A1 | CYCLIC 2-CARBONYLAMINOKETONES AS INHIBITORS OF CRUZIPAIN AND OTHER CYSTEINE PROTEASES | AMURA THERAPEUTICS LIMITED (GB) | 2002-07-25 | — | — | WO | disclosed |
| WO-2002057246-A2 | INHIBITORS OF CRUZIPAIN AND OTHER CYSTEINE PROTEASES | AMURA THERAPEUTICS LIMITED (GB) | 2002-07-25 | — | — | WO | disclosed |
| WO-2002057270-A1 | INHIBITORS OF CRUZIPAIN AND OTHER CYSTEINE PROTEASES | AMURA THERAPEUTICS LIMITED (GB) | 2002-07-25 | — | — | WO | disclosed |
| WO-2002040462-A2 | CYSTEINE PROTEASE INHIBITORS | MEDIVIR UK LIMITED (GB) | 2002-05-23 | — | — | WO | disclosed |
| EP-1178986-A2 | FURANONE DERIVATIVES AS INHIBITORS OF CATHEPSIN S | Medivir UK Ltd (GB) | 2002-02-13 | — | — | EP | disclosed |
| WO-2000069855-A2 | FURANONE DERIVATIVES AS INHIBITORS OF CATHEPSIN S | MEDIVIR UK LIMITED (GB) | 2000-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030186962-A1 | Cysteine protease inhibitors | C1R, CTSS, CTSZ | PLG 176/4885PLAT 342/4885LMNA 1883/4885 |
| US-20150209349-A1 | Piperazine Compounds | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CHRM1, CHRM5 | PLG 3535/4885PLAT 4109/4885LMNA 2350/4885 |
| US-20160015685-A1 | FURO [3, 2-B] PYRR0L-3-0NES AS CATHESPIN S INHIBITORS | CTSS, CTSL, CTSK | PLG 327/4885PLAT 116/4885LMNA 3927/4885 |
| US-20160361295-A1 | FURO[3, 2-B] PYRR0L-3-ONES AS CATHESPIN S INHIBITORS | CTSS, CTSL, CTSK | PLG 389/4885PLAT 186/4885LMNA 4057/4885 |
| US-20150164912-A1 | FURO[3, 2-B] PYRR0L-3-ONES AS CATHESPIN S INHIBITORS | CTSS, CTSL, CTSK | PLG 389/4885PLAT 186/4885LMNA 4057/4885 |
| US-20030203900-A1 | Cysteine protease inhibitors | CTSS, CTSE, CTSV | PLG 116/4885PLAT 273/4885LMNA 3301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.